This Article Full Text (PDF) All Versions of this Article: 1559827608327922v1 3/2/123    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Hopkins, J. Articles by Limacher, M. Search for Related Content Social Bookmarking                         What's this?

The Role of Aspirin in Cardiovascular Disease Prevention in Women

Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida

Marian Limacher, MD

Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida, limacmc{at}medicine.ufl.edu

Cardiovascular disease is the nation's number one killer of women. Through its actions on platelet inhibition, aspirin is an effective agent for primary and secondary cardiovascular disease prevention and for use with cardiac interventions. However, the evidence for aspirin's effectiveness in women differs by age and indication compared to men. As primary prevention, low dose aspirin is recommended for women over age 65 to reduce the risk of myocardial infarction and stroke while younger women at high risk for stroke may benefit from aspirin. Aspirin has benefits in other selected patient groups, including diabetics and patients presenting with ST segment elevation myocardial infarction (STEMI), non-ST segment elevation myocardial infarction acute coronary syndrome (NSTEMI/ACS), peripheral arterial disease, stroke, coronary artery bypass graft (CABG), and percutaneous coronary intervention (PCI). Alternative platelet therapy using dipyridamole or clopidogrel, alone or with aspirin, provides some improved efficacy for reduction in recurrent events for NSTEMI, ASC and PCI, although bleeding risks may be greater. However, dual antiplatelet therapy is not currently recommended for primary prevention in even high risk subjects. Despite the evidence base and guidelines, the use of aspirin in women remains suboptimal and warrants improved provider and patient awareness.

Key Words: cardiovascular disease • aspirin • women • prevention

This version was published on March 1, 2009

American Journal of Lifestyle Medicine, Vol. 3, No. 2, 123-134 (2009)
DOI: 10.1177/1559827608327922


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?